Blog
Autolomous and Vineti form strategic partnership to deliver end to end supply chain management solutions for cell and gene therapy sector
Autolomous LTD, the market leading developer of critical manufacturing management systems for cell and gene therapies, and Vineti, a provider of leading digital enterprise platforms for cell and gene therapy supply chains, today announce a non-exclusive collaborative partnership.
A new Five-minute Guide — seven key challenges in advanced therapy clinical trials
Advanced therapies emerge from advanced science — and must overcome the operational complexity inherent in their patient-centric paradigm when they...
Biopharmaceutical and technology leaders form collaboration to promote standards and a modern patient ID for advanced therapies
Genentech, Takeda, Adaptimmune and other industry leaders join Vineti to form the core of this strategic collaboration. The group is...
Repost: a modern patient ID for personalized medicine
Today, Vineti released an announcement about new industry collaboration around our proposal for a new patient ID for cell and gene therapies....
A fresh start for advanced therapy clinical trials
A look at 2020 and the coming rebound, by the numbers Even before the unpredictable year that was 2020, one...
Introducing new Vineti PTM® flexibility features: next-gen label printing and rescheduling innovations deliver critical workflow options that advanced therapies require
Introducing new Vineti PTM® flexibility features: next-gen label printing and rescheduling innovations deliver critical workflow options that advanced therapies require...
The Vineti Alliance Network — a preview of what’s next
For Vineti, 2020 has been all about continuing to deliver progress for advanced therapies, even amid an unpredictable year. One...
How PTM® Label Printing keeps every patient journey on track
In advanced therapies, little labels — the in-process labels on bags of cells and final drug products — can sometimes...
A true platform is the engine for advanced therapies
A Vineti technology perspective from Chief Technology Officer Phil Calvin Phil Calvin, Vineti’s Chief Technology Officer, is a long-time leader...
How digital solutions solve the “3D chess game” and drive Commercial success
A Vineti technology perspective from Chief Commercial Officer Joe DePinto Joe DePinto, Vineti’s Chief Commercial Officer, is a long-time leader...
A modern patient ID for personalized medicine
Patient-specific therapeutics must be delivered to the patient they are intended to treat. That concept is easy to say —...
Now is the time for proven technology that drives scale
A Vineti technology perspective from CEO and Co-founder Amy DuRoss The underlying medical science behind cell and gene therapies continues...
Vineti Extends Series C Funding Round to $68M with an Expanded Investor Coalition
Today, we’re very excited and honored to announce the extension of our Series C round of funding. We’ve expanded the...